28
Participants
Start Date
January 1, 2011
Primary Completion Date
January 31, 2012
Study Completion Date
August 24, 2012
CC-930
CC-930 50 mg PO daily up to 56 weeks beginning on Day 1
Placebo
Placebo
CC-930
CC-930 100 mg PO daily up to 56 weeks beginning on Day 1
CC-930
C-930 100 mg twice daily approximately 12 hours apart up to 56 weeks beginning on Day 1
Mount Sinai Medical Center, New York
Geisenger Center for Clinical Studies, Danville
Duke University Medical Center, Durham
Medical University of South Carolina, Charleston
University of Miami Miller School of Medicine, Miami
University of Alabama at Birmingham, Birmingham
University of Louisville, Louisville
University of Cincinnati, Cincinnati
University of Minnesota, Minneapolis
Mayo Clinic, Rochester
Baylor College of Medicine, Houston
University of Texas, Galveston
University of Utah, Salt Lake City
Stanford University, Pulmonary & Critical Care Clinic, Stanford
UC Davis Medical Center, Division of Pulmonary and Critical Care Medicine, Sacramento
Vermont Lung Center, Colchester
University of Calgary, Peter Lougheed Centre, Calgary
University of Alberta, Edmonton
Vancouver General Hospital/University of British Columbia, Vancouver
St. Boniface Hospital, Winnipeg
Victoria Hospital, London
Notre-Dame Hospital du CHUM, Montreal
Lead Sponsor
Celgene
INDUSTRY